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Coronary artery bypass grafting (CABG) has been per-formed on patients with ischemic heart disease to im-prove mortality and morbidity. In CABG the internalthoracic artery (ITA) and saphenous vein (SV) are
commonly used as bypass conduits. However, the patency of
venous grafts is worse than that of arterial grafts,1-4 and its mech-
anism has been unclear. This stenosis, called vein graft disease, is
a problem to be addressed clinically.5,6 CABG with several arterial
graft conduits, such as the radial artery, right gastroepiploic artery,
and inferior epigastric artery in addition to the ITA, is clinically
used to avoid vein graft disease.7,8 However, the use of venous
grafts is not yet advisable for patients who require multiple coro-
nary revascularization or for patients undergoing a second opera-
tion. Consequently, the improvement in venous graft patency
might result in further improvements in mortality and morbidity.
Angiotensin II is known to play crucial roles in the proliferation
of vascular tissue in addition to the regulation of blood pressure.9
It is known that angiotensin II is generated from angiotensin I by
both angiotensin-converting enzyme (ACE) and chymasein the
vascular tissue of human subjects, monkeys, dogs, and ham-
sters.10-13 Our recent studies showed that chymase-dependent an-
giotensin II plays an important role in the development of vascular
proliferation in grafted veins.14,15 For example, we demonstrated
that treatment with a chymase inhibitor, Suc-Val-Pro-Phep(Oph)2,
to the vein only once before grafting could prevent the intimal
hyperplasia in grafted veins 7 days after the operation in a dog
model.16 However, it has been unclear how long a chymase inhib-
itor used only once during the operation will suppress intimal
hyperplasia in dog grafted veins. In this study we investigated the
long-term effect of the chymase inhibitor Suc-Val-Pro-Phep(OPh)2
on intimal hyperplasia in dog grafted veins after bypass surgery.
Methods
Drug. A specific chymase inhibitor, Suc-Val-Pro-Phep-
(OPh)2,17 was a gift from Dr Oleksystyn (Wroclaw Tech-
nical University, Poland).
Animal treatment. Twelve beagle dogs weighing 8 to 10
kg were obtained from Japan SLC (Shizuoka, Japan). The
animals were anesthetized with sodium pentobarbital (35
mg/kg administered intravenously). The right external jug-
ular vein was removed and was infiltrated for 20 minutes in
saline containing isosorbide dinitrate (50 mg/mL) and di-
pyridamole (100 mg/mL), which were used as agents for
vascular dilation and antiplatelet action, respectively. Hep-
arin (200 U/kg) was injected into the femoral vein as an
antiplatelet drug, and then the vein was grafted to the
ipsilateral artery. In the group treated with the chymase
inhibitor, the vein was infiltrated for 20 minutes in the
solution used for the placebo group but with the addition of
Suc-Val-Pro-Phep(OPh)2 (10 mol/L). Then the vein was
grafted to the ipsilateral carotid artery. The nonsurgical dogs
were used as a control group. The experimental procedures
for animals were in accordance with the Guide for the Care
and Use of Laboratory Animals (Animal Research Labora-
tory, Osaka Medical College).
Preparation of vascular tissue. Three months after by-
pass surgery, the grafted animals (each group comprised 4
dogs) were anesthetized with sodium pentobarbital (35
mg/kg administered intravenously), and the grafted veins
were removed. Four dogs not undergoing operations used as
a control group were anesthetized with sodium pentobarbi-
tal (35 mg/kg administered intravenously), and the right
external jugular veins were removed.
Extraction for enzyme assay. The grafted and control
veins were minced and homogenized in 10 volumes (wt/vol)
of 20 mmol/L Na-phosphate buffer (pH 7.4). The homoge-
nate was centrifuged at 15,000 rpm for 30 minutes, and the
supernatant was discarded. These steps were repeated twice.
The pellets were resuspended and homogenized in 5 vol-
umes (wt/vol) of 10 mmol/L Na-phosphate buffer (pH 7.4)
containing 2 mol/L KCI and 0.1% Nonidet P-40 (vol/vol).
The homogenate was stored overnight at 4°C and then
centrifuged at 15,000 rpm for 30 minutes. The supernatant
was used as the tissue extract for the measurement of ACE
and chymase activities.
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Measurements of enzyme activities. ACE activity was
measured by incubating the tissue extracts for 1 hour at
37°C with 5 mmol/L hippuril-His-Leu as a substrate in 100
mmol/L phosphate buffer (pH 8.3) containing 800 mmol/L
NaCl.15 The enzyme reaction was terminated by addition of
3% metaphosphoric acid (wt/vol), and the reaction mixture
was placed in ice water for 10 minutes. After centrifugation
of the mixture at 15,000 rpm for 5 minutes, we applied 50
L of the supernatant to an octadecyl silica reversed-phase
column (4.6 mm  25 cm; Tohso, Tokyo, Japan) that had
been equilibrated with 10 mmol/L KH2PO4 and CH3OH
(1:1, pH 3.0) and eluted it with the same solution at a rate
of 0.3 mL/min. Hippuric acid was detected by means of
ultraviolet absorbance at 228 nm. One unit of ACE activity
was defined as the amount of enzyme that cleaved 1 mol
of hippuric acid/min.
Chymase activity was measured by incubating the tissue
extracts for 1 hour at 37°C with 4 mmol/L angiotensin I in
150 mmol/L borax-borate buffer (pH 8.5) containing 5
mmol/L ethylenediamine tetraacetic acid, 8 mmol/L dipyri-
dyl, and 0.77 mmol/L diisopropylfluorophosphate, as de-
scribed previously.15 The enzyme reaction was terminated
by addition of 15% trichloroacetic acid (wt/vol), and the
reaction mixture was placed in ice water for 10 minutes.
After centrifugation of the reaction mixture at 15,000 rpm
for 5 minutes, we applied 50 L of the supernatant to an
octadecyl silica reversed-phase column (ODS 80-Tm, 4.6
mm  25 cm; Tohso) that had been equilibrated with 30%
methanol in 10 mmol/L phosphoric acid and eluted it with
a linear gradient of 30% to 90% methanol in 10 mmol/L
phosphoric acid at a rate of 1 mL/min. Angiotensin II was
detected by means of ultraviolet absorbance at 226 nm. One
unit of chymase activity was defined as the amount of
enzyme that cleaved 1 mol of angiotensin II/min.
Total angiotensin II–forming activity was measured by
incubating tissue extracts for 30 minutes at 37°C with 4
mmol/L angiotensin I in a 20 mmol/L Tris-HCl buffer
containing 0.1 % Triton X-100 (pH 8.5). The reaction was
terminated by the addition of 15% trichloroacetic acid, and
then the mixture was centrifuged at 20,000 rpm for 5
minutes at 4°C. The supernatant (50 L) was applied to a
reversed-phase column (ODS 80-Tm) that was equilibrated
with 30% CH3OH in 10 mmol/L phosphoric acid and eluted
with a linear gradient of 30% to 90% CH3OH in 10 mmol/L
phosphoric acid at a rate of 1 mL/min. Angiotensin II was
detected by means of ultraviolet absorbance at 226 nm. One
unit of chymase activity was defined as the amount of
enzyme that cleaved 1 mol of angiotensin II/min.
The protein concentration was assayed with BCA Protein
Assay Reagent (Pierce, Rockford, Ill) by using bovine se-
rum albumin as a standard.
Histologic analysis of vascular tissue. The vessel seg-
ments were fixed in 10% neutral buffered formalin, embed-
ded in paraffin, and cut into 5-m-thick sections to mini-
mize the variance of neointima formation in the grafted
veins. These sections were stained with van Gieson’s elastic
stain, and the cross-sectional areas of the intima and media
were quantified with an image analysis system (VM-30;
Olympus Optical Co, Tokyo, Japan).
Statistical analysis. All experiments were done with 4
dogs per group. Statistical analysis was performed by means
of 1-way analysis of variance, followed by the Fisher pro-
tected least significant difference. Data are expressed as
means  SEM.
Results
ACE and chymase activities. The ACE activity in
grafted veins in the placebo-treated group was significantly
Figure 1. ACE and chymase activities in control veins, placebo-treated veins, and chymase inhibitor–treated veins.
Each bar represents mean value  SEM (n  4). *P < .05 versus placebo-treated group.
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higher than that in the control group, and it was not affected
by treatment with the chymase inhibitor (control group,
0.57  0.15 mU/mg of protein; placebo-treated group,
2.68  0.19 mU/mg of protein; chymase inhibitor–treated
group, 3.46  0.39 mU/mg of protein; Figure 1).
The chymase activity in the grafted veins in the placebo-
treated group was significantly higher than that in the con-
trol group, and it was significantly reduced by treatment
with the chymase inhibitor (control group, 0.67  0.05
mU/mg of protein; placebo-treated group, 23.25  1.59
mU/mg of protein; chymase inhibitor–treated group, 4.62
0.99 mU/mg of protein; Figure 1).
Total angiotensin II–forming activity. The total angio-
tensin II–forming activity in the placebo-treated group was
significantly higher than that in the control group, and it was
significantly reduced by treatment with the chymase inhib-
itor (control group, 4.37 0.68 mU/mg of protein; placebo-
treated group, 31.02  2.56 mU/mg of protein; chymase
inhibitor–treated group, 8.39  1.48 mU/mg of protein;
Figure 2).
Intimal area, medial area, and ratio of intimal area to
medial area. As shown in Figure 3 in typical sections, the
chymase inhibitor clearly suppressed the intimal area. The
intimal areas of the control group, placebo-treated group,
and chymase inhibitor–treated group were 0.27  0.04,
6.92  0.13, and 1.58  0.10 mm2, respectively (Figure 4).
The intimal area in the placebo-treated group significantly
increased compared with that of the control group, and it
was significantly decreased by treatment with the chymase
inhibitor. The ratio of intimal area to medial area in the
placebo-treated group was significantly increased compared
with that in the control group, and it was also decreased by
treatment with the chymase inhibitor (Figure 4).
Discussion
In the present study we demonstrated that direct and single infil-
tration of grafting veins to a chymase inhibitor maintained
suppression of chymase activity and vascular proliferation 3
months after bypass surgery. Previously, the characterization of
the specific chymase inhibitor we used, Suc-Val-Pro-Phep(OPh)2,
was reported by Oleksyszyn and Powers.17 The half-degradative
time of Suc-Val-Pro-Phep(OPh)2 is approximately 20 hours in
human plasma. In addition, we confirmed that chymase inhibitors,
both chymostatin and Suc-Val-Pro-Phep(OPh)2, dose-dependently
suppressed the angiotensin I–induced vascular contraction in iso-
lated dog arteries in the presence of an ACE inhibitor.14 The
inhibitory concentration of 50% values of Suc-Val-Pro-Phep-
(OPh)2 in dog arteries was 2.8 nmol/L, and the inhibitory concen-
tration of 50% values of Suc-Val-Pro-Phep(OPh)2 in dog arteries
was about 35 times higher than that of chymostatin. These findings
suggest that Suc-Val-Pro-Phep(OPh)2 might be a stable and pow-
erful chymase inhibitor. In fact, the inhibition by the chymase
inhibitor was maintained fully up to 3 months after the operation
in this study, although the inhibitor was used only during the
operation and not continuously. It is reported that chymase, an
enzyme that is present in mast cell granules, is released immedi-
ately from the granules on strong stimulation, binds to extracellular
matrix, and continues to function for several weeks.18,19 Mast cells
in the grafted vessels were activated after the operation, indicating
that chymase was bound to the extracellular matrix immediately
after the operation.16 The chymase inhibitor used in this study
functions irreversibly, which means that the inhibitor, once bound
to the enzyme, continues to inhibit it for a long time. On the other
hand, chymase is also reported to activate stem cell factor, a
typical cytokine that has the ability to induce accumulation of mast
cells.20 Inhibition of chymase activity is thought to prevent the
accumulation of mast cells and resulted in reducing chymase
activity. Therefore, up to 3 months after the operation, the chymase
activity is thought to be fully inhibited by treatment with the
chymase inhibitor.
Angiotensin II plays an important role in vascular proliferation
through the induction of extracellular matrix and growth factors,
both of which participate in the first stages of the repair pro-
cess.21,22 For example, in a rat model neointima formation in
vessels injured by a catheter was prevented with an angiotensin II
type 1 receptor antagonist, and the expression of extracellular
matrix and growth factors was also suppressed.23 Such findings
were also reported with an ACE inhibitor in the rat model.24
However, clinical trials of ACE inhibitor for preventing restenosis
after percutaneous transluminal coronary angioplasty were unsuc-
cessful.25 In graft experimental models an ACE inhibitor was
effective in preventing vascular proliferation in rats, whereas in
baboons it was not.26,27 Such species differences in the effects of
ACE inhibitors on neointimal formation might depend on species
differences in the angiotensin II–forming pathways. Rat vascular
tissues contain ACE as the only angiotensin II–forming enzyme,
whereas vascular tissues of human subjects, monkeys, dogs, and
hamsters contain chymase in addition to ACE as angiotensin
II–forming enzymes.10-13 In dog vessels injured by a catheter, an
angiotensin II type 1 (AT1) receptor antagonist was effective in
Figure 2. Total angiotensin II–forming activity in control veins,
placebo-treated veins, and chymase inhibitor–treated veins. Each
bar represents mean value  SEM (n  4). *P < .05 versus
placebo-treated group.
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preventing the intimal formation, but an ACE inhibitor was inef-
fective.28,29 Therefore it is thought that ACE inhibitors could not
suppress chymase-dependent angiotensin II formation, resulting in
vascular proliferation in primate and dog vessels, despite the
prevention of such proliferation in rats. In the present study the
chymase inhibitor significantly suppressed the vascular prolifera-
tion, despite the increase of the ACE activity in the grafted veins.
The inhibition of chymase, but not ACE, might be useful for
preventing the vascular proliferation of grafted veins.
We reported that an angiotensin II type 1 receptor antagonist,
L-158,809, suppressed vascular proliferation in dog grafted
veins.14 In the present study the chymase inhibitor significantly
suppressed not only the chymase activity but also total angiotensin
II–forming activity in the grafted veins. These findings suggest that
total angiotensin II–forming activity in grafted veins depends
mainly on the chymase-dependent angiotensin II–forming path-
way. Recently, we investigated the activities of the angiotensin
II–forming enzymes ACE and chymase in human SVs and ITAs
and reported that the chymase activity and total angiotensin II–
forming activity were significantly increased in the SV compared
with that in the ITA,30 suggesting that a higher chymase activity in
the SV might play an important role in vein graft diseases.
In conclusion, we confirmed that the chymase inhibitor was
effective for the inhibition of chymase activity and intimal hyper-
plasia in grafted veins for 3 months after bypass surgery and that
chymase inhibitors might be useful for preventing intimal hyper-
plasia in grafted veins.
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